Valuation: NeoGenomics, Inc.

Market Cap 2.18B 1.95B 1.79B 1.63B 3.07B 205B 3.17B 21.53B 8.58B 109B 8.18B 8B 345B P/E 2026 *
-70.6x
P/E 2027 * -64.5x
Enterprise Value 2.18B 1.95B 1.79B 1.63B 3.07B 205B 3.17B 21.53B 8.58B 109B 8.18B 8B 345B EV / Sales 2026 *
2.7x
EV / Sales 2027 * 2.46x
Free-Float
96.13%
Yield 2026 *
-
Yield 2027 * -
1 day+2.12%
1 week-3.11%
Current month-3.11%
1 month+5.12%
3 months+1.63%
6 months+87.95%
Current year+43.20%
1 week 15.9
Extreme 15.9
17.39
1 month 15.86
Extreme 15.86
18.15
Current year 7.06
Extreme 7.065
20.15
1 year 7.06
Extreme 7.065
20.15
3 years 4.72
Extreme 4.72
21.22
5 years 4.72
Extreme 4.72
44.26
10 years 4.72
Extreme 4.72
61.57
Manager TitleAgeSince
Chief Executive Officer 65 31/03/2025
Director of Finance/CFO 57 01/03/2026
President 54 31/03/2025
Director TitleAgeSince
Chairman 64 06/10/2021
Director/Board Member 63 18/07/2017
Director/Board Member 69 14/07/2020
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Exercice

Chairperson

42,035 0.0327%
01/09/26 Tax

General Counsel

-2,692 0.0021%
21/08/26 Exercice

Chairperson

67,272 0.0524%
Change 5-day change 1-year change 3-year change Capi.($)
+2.12%-3.11%+67.06%+6.38% 2.18B
+3.10%-7.09%+6.15%+21.96% 107B
-2.46%+4.61%+3.86%+113.77% 103B
-14.59%-25.01%+55.67%+651.50% 45.05B
+0.64%+9.80%+10.16%+103.96% 32.96B
+0.90%+1.43%+45.05%+78.08% 29.77B
+0.35%+1.51%+42.41%+91.53% 28.12B
-1.09%+3.69%+38.03%+418.73% 22.55B
-0.37%+1.18%-17.81%-16.07% 20.05B
-0.26%-1.91%-7.00%+28.33% 16.76B
Average +0.16%-1.92%+24.36%+149.82% 40.81B
Weighted average by Cap. -0.20%-2.56%+17.07%+150.46%

Financials

2026 *2027 *
Net sales 808M 725M 662M 605M 1.14B 75.97B 1.18B 7.99B 3.18B 40.54B 3.03B 2.97B 128B 887M 795M 727M 664M 1.25B 83.37B 1.29B 8.76B 3.49B 44.49B 3.33B 3.26B 140B
Net income -31.2M -27.98M -25.57M -23.34M -43.98M -2.93B -45.37M -308M -123M -1.56B -117M -115M -4.94B -34.24M -30.71M -28.07M -25.62M -48.28M -3.22B -49.8M -338M -135M -1.72B -129M -126M -5.42B
Net Debt - -
Projected Income Statement - Annual - NeoGenomics, Inc.
Logo NeoGenomics, Inc.
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing, interpretation and consultative services, molecular and NGS testing, comprehensive technical and professional services offering, clinical trials and research, validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Molecular testing and others.
Employees
2,500
Date Price Change Volume
06/11/26 US$16.84 +2.12% 1,314,124
05/11/26 US$16.49 -3.85% 2,105,393
04/11/26 US$17.15 +1.90% 1,149,926
03/11/26 US$16.83 +2.06% 1,810,145
02/11/26 US$16.49 -5.12% 1,706,095
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
MarketScreener Ratings - NeoGenomics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
16.84USD
Average target price
23.40USD
Spread / Average Target
+38.95%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - NeoGenomics, Inc.